Open an account

Alaunos Therapeutics

TCRT · NASDAQ

$2.97−$0.16 (−5.11%)TodayMarket closed ·
Prev close $3.13

About TCRT

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. The company is headquartered in Fort Lauderdale, Florida and currently employs 1 full-time employees. The company went IPO on 2004-08-20. The firm focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The firm is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The firm has not generated any revenues.

Employees
1
Headquarters
FORT LAUDERDALE, Florida
Listed
Aug 20, 2004
Sector
Health Care
Industry
Biotechnology
Website
alaunos.com

TCRT key statistics

Market cap
8.69M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
20.95M
Volume
3.71M
Open price
$2.77
High today
$3.26
Low today
$2.76
52 Week high
$4.50
52 Week low
$0.719

Alaunos Therapeutics (TCRT) at a glance

Alaunos Therapeutics (TCRT) last traded at $2.97, with a market cap of 8.69M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.76 and $3.26. The current price is 7.6% above the day's low and 8.9% below its high.

Volume so far is 3.71M shares, below the average of 20.95M shares a day.

Over the past year Alaunos Therapeutics has ranged from $0.719 to $4.50, and now sits 60% of the way up that range.

Alaunos Therapeutics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q4 FY23 it reported -$4.90 per share against an estimate of -$4.59.

TCRT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 26.7% on average.

  1. Q1 FY22: reported -$7.50 per share against an estimate of -$10.10
  2. Q2 FY22: reported -$7.50 per share against an estimate of -$10.45
  3. Q3 FY22: reported -$6.00 per share against an estimate of -$11.63
  4. Q4 FY22: reported -$6.00 per share against an estimate of -$10.20
  5. Q1 FY23: reported -$6.00 per share against an estimate of -$6.38
  6. Q2 FY23: reported -$6.00 per share against an estimate of -$6.73
  7. Q3 FY23: reported -$6.00 per share against an estimate of -$5.36
  8. Q4 FY23: reported -$4.90 per share against an estimate of -$4.59

TCRT news

  • Vandana Singh

    Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?

  • Press releasePRNewswire

    Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.

  • Market-Moving News for September 18th

  • Mohd Haider

    Alaunos Therapeutics (TCRT) Stock Soars Over 29% After-Hours: Here's What's Going On

  • Press releasePRNewswire

    Valion Bio Appoints Melinda Lackey as General Counsel

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Vishaal Sanjay

    4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week

Similar companies

Companies in the same industry as Alaunos Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.